Tags

Type your tag names separated by a space and hit enter

Waning immunity to pertussis following 5 doses of DTaP.
Pediatrics. 2013 Apr; 131(4):e1047-52.Ped

Abstract

OBJECTIVE

To assess the risk of pertussis by time since vaccination in children in Minnesota and Oregon who received 5 doses of acellular pertussis vaccines (DTaP).

METHODS

These cohort analyses included Minnesota and Oregon children born between 1998 and 2003 who had 5 DTaP doses recorded in state Immunization Information Systems. Immunization records and statewide pertussis surveillance data were combined. Incidence rates and risk ratios for pertussis were calculated for the 6 years after receipt of the fifth DTaP dose.

RESULTS

The cohorts included 224,378 Minnesota children and 179,011 from Oregon; 458 and 89 pertussis cases were identified in Minnesota and Oregon, respectively. Pertussis incidence rates rose each year of follow-up: 15.6/100,000 (95% confidence interval [CI]: 11.1-21.4) at year 1 to 138.4/100,000 (CI: 113.3-166.9) at year 6 (Minnesota); 6.2/100,000 (CI: 3.3-10.6) in year 1 to 24.4/100,000 (CI: 15.0-37.8) in year 6 (Oregon). Risk ratios increased from 1.9 (CI: 1.3-2.9) in year 2 to 8.9 (CI: 6.0-13.0) in year 6 (Minnesota) and from 1.3 (CI: 0.6-2.8) in year 2 to 4.0 (CI: 1.9-8.4) in year 6 (Oregon).

CONCLUSIONS

This evaluation reports steady increase in risk of pertussis in the years after completion of the 5-dose DTaP series. This rise is likely attributable in part to waning immunity from DTaP vaccines. Continuing to monitor disease burden and vaccine effectiveness in fully vaccinated children in coming years will be important to assess ongoing risk as additional cohorts vaccinated solely with acellular pertussis vaccines are introduced.

Authors+Show Affiliations

Centers for Disease Control and Prevention, Atlanta, Georgia, USA. sara.y.tartof@kp.orgNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

23478868

Citation

Tartof, Sara Y., et al. "Waning Immunity to Pertussis Following 5 Doses of DTaP." Pediatrics, vol. 131, no. 4, 2013, pp. e1047-52.
Tartof SY, Lewis M, Kenyon C, et al. Waning immunity to pertussis following 5 doses of DTaP. Pediatrics. 2013;131(4):e1047-52.
Tartof, S. Y., Lewis, M., Kenyon, C., White, K., Osborn, A., Liko, J., Zell, E., Martin, S., Messonnier, N. E., Clark, T. A., & Skoff, T. H. (2013). Waning immunity to pertussis following 5 doses of DTaP. Pediatrics, 131(4), e1047-52. https://doi.org/10.1542/peds.2012-1928
Tartof SY, et al. Waning Immunity to Pertussis Following 5 Doses of DTaP. Pediatrics. 2013;131(4):e1047-52. PubMed PMID: 23478868.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Waning immunity to pertussis following 5 doses of DTaP. AU - Tartof,Sara Y, AU - Lewis,Melissa, AU - Kenyon,Cynthia, AU - White,Karen, AU - Osborn,Andrew, AU - Liko,Juventila, AU - Zell,Elizabeth, AU - Martin,Stacey, AU - Messonnier,Nancy E, AU - Clark,Thomas A, AU - Skoff,Tami H, Y1 - 2013/03/11/ PY - 2013/3/13/entrez PY - 2013/3/13/pubmed PY - 2013/5/22/medline SP - e1047 EP - 52 JF - Pediatrics JO - Pediatrics VL - 131 IS - 4 N2 - OBJECTIVE: To assess the risk of pertussis by time since vaccination in children in Minnesota and Oregon who received 5 doses of acellular pertussis vaccines (DTaP). METHODS: These cohort analyses included Minnesota and Oregon children born between 1998 and 2003 who had 5 DTaP doses recorded in state Immunization Information Systems. Immunization records and statewide pertussis surveillance data were combined. Incidence rates and risk ratios for pertussis were calculated for the 6 years after receipt of the fifth DTaP dose. RESULTS: The cohorts included 224,378 Minnesota children and 179,011 from Oregon; 458 and 89 pertussis cases were identified in Minnesota and Oregon, respectively. Pertussis incidence rates rose each year of follow-up: 15.6/100,000 (95% confidence interval [CI]: 11.1-21.4) at year 1 to 138.4/100,000 (CI: 113.3-166.9) at year 6 (Minnesota); 6.2/100,000 (CI: 3.3-10.6) in year 1 to 24.4/100,000 (CI: 15.0-37.8) in year 6 (Oregon). Risk ratios increased from 1.9 (CI: 1.3-2.9) in year 2 to 8.9 (CI: 6.0-13.0) in year 6 (Minnesota) and from 1.3 (CI: 0.6-2.8) in year 2 to 4.0 (CI: 1.9-8.4) in year 6 (Oregon). CONCLUSIONS: This evaluation reports steady increase in risk of pertussis in the years after completion of the 5-dose DTaP series. This rise is likely attributable in part to waning immunity from DTaP vaccines. Continuing to monitor disease burden and vaccine effectiveness in fully vaccinated children in coming years will be important to assess ongoing risk as additional cohorts vaccinated solely with acellular pertussis vaccines are introduced. SN - 1098-4275 UR - https://www.unboundmedicine.com/medline/citation/23478868/Waning_immunity_to_pertussis_following_5_doses_of_DTaP_ L2 - http://pediatrics.aappublications.org/cgi/pmidlookup?view=long&pmid=23478868 DB - PRIME DP - Unbound Medicine ER -